Conducting a clinical trial is a huge and complex undertaking, and
there are, more often than not, challenges. And in an undertaking
as scientifically and logistically complex as a pharmaceutical trial,
there’s a lot that can go wrong. In fact, almost 50% of Phase III trials
fail. They fail because the drug did not work or because the design of
the trial was fatally flawed. But they can fail for other reasons, too,
such as poor execution. Karen Chu and Dr Sy Pretorius at PAREXEL
claim that fortunately, troubled trials can often be rescued.